



BRITISH COLUMBIA  
CENTRE *for* EXCELLENCE  
*in* HIV/AIDS

# B.C. HIV/AIDS Drug Treatment Program

Monthly Report

May 2020





© 2020 BC Centre for Excellence in HIV/AIDS

**DISCLAIMER:** This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

### **BC Centre for Excellence in HIV/AIDS Drug Treatment Program**

St. Paul's Hospital  
608 - 1081 Burrard Street  
Vancouver, BC  
V6Z 1Y6

Tel: 604.806.8515  
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677  
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222  
Website: [www.cfenet.ubc.ca](http://www.cfenet.ubc.ca)  
Email: [info@cfenet.ubc.ca](mailto:info@cfenet.ubc.ca)

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)





## EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





### TABLE OF CONTENTS

#### 1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

#### 2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





## Table of Contents, cont'd...

### 3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

### 4. Health Authority Tables

#### INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

### 5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

May 2020

N = 7415



Health Authority	Male	Female	All
FRASER	1454	455	1909
INTERIOR	420	103	523
NORTHERN	134	89	223
VANCOUVER COASTAL	3334	451	3785
VANCOUVER ISLAND	788	158	946
	<b>6130</b>	<b>1256</b>	<b>7386</b>
		<b>Unknown/not stated:</b>	<b>29</b>
		<b>Total:</b>	<b>7415</b>

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






## 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (May 2015 - May 2020)






### 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (May 2015 - May 2020)








1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (May 2015 - May 2020)






1.5 BC-CfE Enrollment: New Antiretroviral Participants  
(May 2015 - May 2020)






1.6 Percent Distribution of Active Participants by CD4 Count  
(May 2015 - May 2020)






1.7 Percent Distribution of Inactive Participants by CD4 Count  
(May 2015 - May 2020)






### 1.8 Active and Inactive Participants (May 2015 - May 2020)






### 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (May 2015 - May 2020)






### 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (May 2015 - May 2020)





### 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT


(May 2015 - May 2020)








1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT  
(May 2015 - May 2020)






### 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(May 2015 - May 2020)






### 1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (May 2015 - May 2020)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(May 2015 - May 2020)






### 1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (May 2015 - May 2020)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT

(May 2015 - May 2020)






1.18 Baseline CD4 for Antiretroviral First Starts (May 2015 - May 2020)






**1.19 DTP Participants with PVL Measurement within previous five years, and never on ART  
(May 2015 - May 2020)**







### 1.20 Cumulative Resistance Testing Results by Resistance Category (May 2015 - May 2020)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (May 2015 - May 2020)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2020  
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	28	5	0	5	2	580	5	<40	3
1988	29	6	0	6	4	325	6	<40	3
1989	27	52	1	53	31	460	48	<40	3
1990	26	54	1	55	34	520	51	<40	3
1991	26	37	3	40	19	560	36	<40	3
1992	26	62	5	67	37	660	61	<40	3
1993	25	130	16	146	111	560	131	<40	3
1994	23	80	11	91	61	570	84	<40	3
1995	23	130	22	152	106	530	131	<40	3
1996	21	327	50	377	250	554	331	<40	3
1997	19	274	34	308	207	650	270	<40	3
1998	18	192	44	236	159	590	203	<40	3
1999	19	158	38	196	126	565	163	<40	3
2000	19	121	34	155	106	620	136	<40	3
2001	18	115	28	143	98	570	125	<40	3
2002	17	122	27	149	102	580	127	<40	3
2003	17	148	31	179	117	630	155	<40	3
2004	16	153	39	192	127	590	164	<40	3
2005	15	184	47	231	156	620	192	<40	3
2006	14	183	41	224	154	595	201	<40	3
2007	13	242	48	290	196	630	243	<40	3
2008	12	274	69	343	232	635	296	<40	3
2009	11	307	66	373	243	650	317	<40	3
2010	10	278	76	354	238	665	295	<40	3
2011	9	327	76	403	269	680	338	<40	3
2012	8	270	63	333	222	670	283	<40	3
2013	7	268	69	337	221	650	281	<40	3
2014	6	284	54	338	214	715	284	<40	3
2015	5	290	44	334	224	660	286	<40	3
2016	4	278	56	334	211	670	274	<40	3
2017	3	226	36	262	189	650	228	<40	3
2018	2	205	55	260	186	660	236	<40	3

**Definitions:**

**On treatment** defined as being on ARV therapy in the specified month and not reported deceased

**Duration** defined as cumulative years on ARV therapy, excluding periods of treatment interruption

**Current CD4 and PVL tests** defined as tests done in the last 6 months (most recent)

**Current ARV** defined as number of ARV drugs in the current regimen





**2.1 Duration of ARV treatment in the Province of BC, 1987-2020  
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Current CD4 Median	Current PVL (n)	Current PVL Median	Current ARV Median
2019	1	242	48	290	222	590	267	<40	3
2020	0	116	25	141	118	600	131	<40	3
<b>Total:</b>		<b>6140</b>	<b>1257</b>	<b>7397</b>					

**Definitions:**

**On treatment** defined as being on ARV therapy in the specified month and not reported deceased

**Duration** defined as cumulative years on ARV therapy, excluding periods of treatment interruption

**Current CD4 and PVL tests** defined as tests done in the last 6 months (most recent)

**Current ARV** defined as number of ARV drugs in the current regimen





## 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2019	7393	788	2456	<40	2146	610
FEB-2019	7368	797	1854	<40	1583	620
MAR-2019	7407	790	2085	<40	1753	610
APR-2019	7358	797	2141	<40	1746	610
MAY-2019	7416	792	2127	<40	1766	620
JUN-2019	7359	803	1926	<40	1594	620
JUL-2019	7371	812	2111	<40	1695	620
AUG-2019	7366	809	2106	<40	1621	600
SEP-2019	7339	806	2012	<40	1568	600
OCT-2019	7390	785	2140	<40	1744	620
NOV-2019	7343	780	2026	<40	1579	630
DEC-2019	7344	777	1700	<40	1286	610
JAN-2020	7357	774	2226	<40	1704	610
FEB-2020	7331	779	1882	<40	1399	626
MAR-2020	7391	769	1630	<40	1168	620
APR-2020	7419	770	770	<40	538	600
MAY-2020	7415	776	1187	<40	786	610

**Definitions:**

**Active patient** defined as being on ARV treatment in the specified month

**Therapy days** defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

**PVL and CD4 tests** defined as tests done in the specified month





### 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2019	1459	3449	73	73	65	350
FEB-2019	1490	3368	75	108	66	590
MAR-2019	1458	3509	74	636	61	400
APR-2019	1497	3395	81	<50	71	480
MAY-2019	1443	3650	78	87	69	450
JUN-2019	1504	3422	79	<40	71	550
JUL-2019	1492	3497	71	<40	58	530
AUG-2019	1512	3451	81	<40	68	515
SEP-2019	1541	3320	95	<40	78	580
OCT-2019	1482	3624	81	102	69	470
NOV-2019	1502	3575	69	<40	59	560
DEC-2019	1487	3659	58	<40	49	480
JAN-2020	1462	3783	71	255	46	435
FEB-2020	1501	3647	72	<40	57	480
MAR-2020	1455	3866	52	<40	35	470
APR-2020	1427	4008	24	71	17	570
MAY-2020	1438	4003	42	<50	28	500

**Definitions:**

**Inactive patient** defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs)

**Days off therapy** defined as number of days elapsed since last ARV treatment

**PVL and CD4 tests** defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2019	7364	1459	14	20	191	159	35	13564
FEB-2019	7349	1490	7	16	160	181	-15	13593
MAR-2019	7371	1458	15	13	187	150	22	13613
APR-2019	7325	1497	10	15	152	182	-46	13641
MAY-2019	7389	1443	11	21	197	137	64	13683
JUN-2019	7330	1504	14	13	137	191	-59	13704
JUL-2019	7344	1492	13	13	181	164	14	13727
AUG-2019	7338	1512	12	18	170	175	-6	13763
SEP-2019	7311	1541	14	15	181	203	-27	13790
OCT-2019	7324	1482	3	13	223	150	13	13819
NOV-2019	7317	1502	9	17	165	170	-7	13852
DEC-2019	7313	1487	8	12	164	156	-4	13879
JAN-2020	7329	1462	10	12	181	155	16	13902
FEB-2020	7298	1501	12	19	141	171	-31	13938
MAR-2020	7363	1455	14	23	212	152	65	13974
APR-2020	7395	1427	12	8	161	123	32	13999
MAY-2020	7397	1438	10	15	130	129	2	14024

**Definitions:**

**Currently on ARV Therapy** defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

**Currently off ARV Therapy** defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

**Deceased** defined as deceased in the specified month, and being on ARV treatment in the previous month

**First Starts** defined as starting ARV treatment in the specified month for the first time (ARV naive)

**Experienced Starts** defined as starting ARV treatment in the specified month, but previously being treated with ARVs

**New Inactive** defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month

**Net Change** is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





### 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2019	55	6800	485	53	<b>7393</b>	0.74%	91.98%	6.56%	0.72%	<b>100.00%</b>
FEB-2019	54	6775	490	49	<b>7368</b>	0.73%	91.95%	6.65%	0.67%	<b>100.00%</b>
MAR-2019	60	6808	489	50	<b>7407</b>	0.81%	91.91%	6.60%	0.68%	<b>100.00%</b>
APR-2019	57	6764	489	48	<b>7358</b>	0.77%	91.93%	6.65%	0.65%	<b>100.00%</b>
MAY-2019	56	6824	491	45	<b>7416</b>	0.76%	92.02%	6.62%	0.61%	<b>100.00%</b>
JUN-2019	58	6772	481	48	<b>7359</b>	0.79%	92.02%	6.54%	0.65%	<b>100.00%</b>
JUL-2019	61	6773	489	48	<b>7371</b>	0.83%	91.89%	6.63%	0.65%	<b>100.00%</b>
AUG-2019	60	6775	481	50	<b>7366</b>	0.81%	91.98%	6.53%	0.68%	<b>100.00%</b>
SEP-2019	57	6745	486	51	<b>7339</b>	0.78%	91.91%	6.62%	0.69%	<b>100.00%</b>
OCT-2019	61	6789	488	52	<b>7390</b>	0.83%	91.87%	6.60%	0.70%	<b>100.00%</b>
NOV-2019	60	6747	486	50	<b>7343</b>	0.82%	91.88%	6.62%	0.68%	<b>100.00%</b>
DEC-2019	61	6757	478	48	<b>7344</b>	0.83%	92.01%	6.51%	0.65%	<b>100.00%</b>
JAN-2020	59	6757	485	56	<b>7357</b>	0.80%	91.84%	6.59%	0.76%	<b>100.00%</b>
FEB-2020	58	6738	476	59	<b>7331</b>	0.79%	91.91%	6.49%	0.80%	<b>100.00%</b>
MAR-2020	60	6794	486	51	<b>7391</b>	0.81%	91.92%	6.58%	0.69%	<b>100.00%</b>
APR-2020	61	6824	483	51	<b>7419</b>	0.82%	91.98%	6.51%	0.69%	<b>100.00%</b>
MAY-2020	60	6823	481	51	<b>7415</b>	0.81%	92.02%	6.49%	0.69%	<b>100.00%</b>

**Definitions:**

**Number of Drugs** is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)







**2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT**

	lamivudine		abacavir		zidovudine		stavudine		didanosine		tenofovir <TAF>		tenofovir <TDF>	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2019	8 23%	3467 48%	7 20%	3254 45%	1 3%	45 1%	0 0%	4 0%	0 0%	1 0%	1 3%	519 7%	26 74%	3358 47%
FEB-2019	13 45%	3457 48%	12 41%	3256 45%	0 0%	44 1%	0 0%	1 0%	0 0%	1 0%	3 10%	541 8%	13 45%	3306 46%
MAR-2019	6 30%	3470 48%	6 30%	3274 45%	0 0%	43 1%	0 0%	2 0%	0 0%	0 0%	2 10%	559 8%	12 60%	3305 46%
APR-2019	12 43%	3469 48%	12 43%	3278 46%	0 0%	43 1%	0 0%	2 0%	0 0%	0 0%	2 7%	586 8%	14 50%	3245 45%
MAY-2019	14 34%	3498 48%	14 34%	3308 46%	0 0%	43 1%	0 0%	2 0%	0 0%	1 0%	4 10%	593 8%	23 56%	3258 45%
JUN-2019	3 14%	3479 49%	3 14%	3291 46%	0 0%	43 1%	0 0%	2 0%	0 0%	1 0%	2 10%	608 8%	16 76%	3199 45%
JUL-2019	8 36%	3504 49%	8 36%	3325 46%	0 0%	38 1%	0 0%	1 0%	0 0%	1 0%	1 5%	625 9%	13 59%	3178 44%
AUG-2019	14 39%	3515 49%	12 33%	3340 47%	2 6%	41 1%	0 0%	1 0%	0 0%	1 0%	2 6%	630 9%	20 56%	3144 44%
SEP-2019	5 19%	3494 49%	5 19%	3318 46%	0 0%	39 1%	0 0%	1 0%	0 0%	1 0%	5 19%	653 9%	17 63%	3122 44%
OCT-2019	4 14%	3513 49%	2 7%	3331 46%	0 0%	38 1%	0 0%	1 0%	0 0%	1 0%	1 4%	668 9%	23 82%	3143 44%
NOV-2019	8 24%	3458 48%	7 21%	3281 46%	1 3%	37 1%	0 0%	1 0%	0 0%	1 0%	6 18%	728 10%	19 58%	3114 44%
DEC-2019	1 4%	3437 48%	1 4%	3259 46%	0 0%	37 1%	0 0%	1 0%	0 0%	1 0%	13 48%	855 12%	13 48%	3052 43%
JAN-2020	2 9%	3403 47%	2 9%	3227 45%	0 0%	34 0%	0 0%	1 0%	0 0%	0 0%	9 39%	1024 14%	12 52%	2962 41%
FEB-2020	3 8%	3354 47%	3 8%	3182 45%	0 0%	33 0%	0 0%	1 0%	0 0%	0 0%	16 44%	1169 16%	17 47%	2825 40%
MAR-2020	5 14%	3327 46%	5 14%	3162 44%	1 3%	34 0%	0 0%	1 0%	0 0%	0 0%	20 56%	1327 18%	11 31%	2720 38%
APR-2020	6 24%	3303 46%	5 20%	3142 43%	1 4%	35 0%	0 0%	0 0%	0 0%	0 0%	8 32%	1405 19%	11 44%	2642 37%
MAY-2020	1 4%	3280 45%	0 0%	3118 43%	0 0%	36 0%	0 0%	0 0%	0 0%	0 0%	13 54%	1483 21%	11 46%	2606 36%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





Monthly Report

**2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (continued)**

	emtricitabine			
	Initial		All	
JAN-2019	27	77%	3697	51%
FEB-2019	16	55%	3674	51%
MAR-2019	14	70%	3702	51%
APR-2019	16	57%	3662	51%
MAY-2019	27	66%	3689	51%
JUN-2019	18	86%	3644	51%
JUL-2019	14	64%	3651	51%
AUG-2019	22	61%	3626	51%
SEP-2019	22	81%	3623	51%
OCT-2019	24	86%	3664	51%
NOV-2019	25	76%	3672	51%
DEC-2019	26	96%	3714	52%
JAN-2020	21	91%	3762	52%
FEB-2020	33	92%	3781	53%
MAR-2020	30	83%	3857	54%
APR-2020	19	76%	3895	54%
MAY-2020	23	96%	3923	54%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





**2.7 Number of Participants on Protease Inhibitor by INGREDIENT**

	fosamprenavir		atazanavir		darunavir		lopinavir		nelfinavir		ritonavir		saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2019	0 0%	6 0%	1 8%	1097 40%	11 92%	1475 54%	0 0%	140 5%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
FEB-2019	0 0%	5 0%	2 18%	1069 40%	9 82%	1472 55%	0 0%	138 5%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
MAR-2019	0 0%	5 0%	2 40%	1053 39%	3 60%	1486 55%	0 0%	132 5%	0 0%	1 0%	0 0%	1 0%	0 0%	7 0%
APR-2019	0 0%	5 0%	1 10%	1027 39%	7 70%	1477 56%	2 20%	132 5%	0 0%	2 0%	0 0%	1 0%	0 0%	7 0%
MAY-2019	0 0%	5 0%	1 8%	1033 39%	11 92%	1478 56%	0 0%	130 5%	0 0%	2 0%	0 0%	1 0%	0 0%	6 0%
JUN-2019	0 0%	5 0%	0 0%	1001 39%	9 100%	1465 57%	0 0%	119 5%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
JUL-2019	0 0%	5 0%	0 0%	981 38%	6 100%	1483 58%	0 0%	111 4%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
AUG-2019	0 0%	5 0%	0 0%	968 38%	11 92%	1459 57%	1 8%	112 4%	0 0%	1 0%	0 0%	1 0%	0 0%	5 0%
SEP-2019	0 0%	4 0%	1 8%	955 37%	12 92%	1481 58%	0 0%	110 4%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
OCT-2019	0 0%	4 0%	1 7%	958 37%	13 93%	1489 58%	0 0%	109 4%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
NOV-2019	0 0%	4 0%	0 0%	941 37%	3 100%	1469 58%	0 0%	101 4%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
DEC-2019	0 0%	4 0%	0 0%	924 37%	7 100%	1466 59%	0 0%	100 4%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
JAN-2020	0 0%	2 0%	0 0%	910 37%	6 86%	1466 59%	1 14%	96 4%	0 0%	0 0%	0 0%	1 0%	0 0%	6 0%
FEB-2020	0 0%	2 0%	1 11%	873 36%	8 89%	1454 60%	0 0%	96 4%	0 0%	0 0%	0 0%	1 0%	0 0%	6 0%
MAR-2020	0 0%	2 0%	1 10%	860 36%	9 90%	1436 60%	0 0%	93 4%	0 0%	0 0%	0 0%	1 0%	0 0%	6 0%
APR-2020	0 0%	2 0%	0 0%	839 36%	4 80%	1416 60%	1 20%	93 4%	0 0%	0 0%	0 0%	1 0%	0 0%	6 0%
MAY-2020	0 0%	2 0%	1 10%	835 36%	9 90%	1416 60%	0 0%	90 4%	0 0%	0 0%	0 0%	0 0%	0 0%	6 0%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





Monthly Report

**2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)**

	tipranavir			
	Initial		All	
JAN-2019	0	0%	1	0%
FEB-2019	0	0%	1	0%
MAR-2019	0	0%	1	0%
APR-2019	0	0%	1	0%
MAY-2019	0	0%	1	0%
JUN-2019	0	0%	1	0%
JUL-2019	0	0%	1	0%
AUG-2019	0	0%	1	0%
SEP-2019	0	0%	1	0%
OCT-2019	0	0%	1	0%
NOV-2019	0	0%	1	0%
DEC-2019	0	0%	1	0%
JAN-2020	0	0%	1	0%
FEB-2020	0	0%	1	0%
MAR-2020	0	0%	1	0%
APR-2020	0	0%	1	0%
MAY-2020	0	0%	0	0%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





**2.8 Number of Participants on Non-Nucleosides by INGREDIENT**

	doravirine		efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2019	0 0%	0 0%	4 80%	669 35%	0 0%	221 12%	1 20%	695 37%	0 0%	318 17%
FEB-2019	0 0%	0 0%	2 67%	667 35%	1 33%	226 12%	0 0%	683 36%	0 0%	313 17%
MAR-2019	0 0%	0 0%	3 75%	660 35%	0 0%	223 12%	1 25%	680 36%	0 0%	322 17%
APR-2019	0 0%	0 0%	4 100%	645 35%	0 0%	222 12%	0 0%	677 36%	0 0%	320 17%
MAY-2019	0 0%	0 0%	5 100%	647 35%	0 0%	217 12%	0 0%	672 36%	0 0%	322 17%
JUN-2019	0 0%	0 0%	3 75%	633 35%	0 0%	211 12%	0 0%	664 36%	1 25%	320 18%
JUL-2019	0 0%	1 0%	2 100%	633 35%	0 0%	209 11%	0 0%	657 36%	0 0%	322 18%
AUG-2019	0 0%	1 0%	2 100%	624 35%	0 0%	205 11%	0 0%	647 36%	0 0%	324 18%
SEP-2019	0 0%	1 0%	4 80%	607 34%	0 0%	207 12%	0 0%	622 35%	1 20%	324 18%
OCT-2019	0 0%	1 0%	6 60%	608 35%	1 10%	209 12%	2 20%	596 34%	1 10%	330 19%
NOV-2019	0 0%	1 0%	5 71%	612 37%	0 0%	208 12%	1 14%	525 31%	1 14%	326 20%
DEC-2019	0 0%	1 0%	3 100%	607 37%	0 0%	203 12%	0 0%	513 31%	0 0%	324 20%
JAN-2020	0 0%	1 0%	2 100%	589 36%	0 0%	202 13%	0 0%	501 31%	0 0%	325 20%
FEB-2020	0 0%	1 0%	4 100%	558 36%	0 0%	198 13%	0 0%	483 31%	0 0%	320 21%
MAR-2020	0 0%	1 0%	4 100%	547 36%	0 0%	195 13%	0 0%	464 31%	0 0%	315 21%
APR-2020	0 0%	1 0%	6 86%	542 36%	0 0%	190 13%	0 0%	456 30%	1 14%	313 21%
MAY-2020	0 0%	1 0%	1 50%	540 36%	0 0%	194 13%	0 0%	453 30%	1 50%	306 20%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Doravirine not currently available on BC-CfE Formulary





**2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT**

	bictegravir		dolutegravir		elvitegravir		maraviroc		raltegravir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2019	0 0%	16 0%	15 75%	2429 63%	4 20%	729 19%	0 0%	39 1%	1 5%	651 17%
FEB-2019	0 0%	27 1%	16 73%	2431 63%	5 23%	726 19%	0 0%	40 1%	1 5%	651 17%
MAR-2019	0 0%	27 1%	8 62%	2479 64%	5 38%	745 19%	0 0%	38 1%	0 0%	647 17%
APR-2019	0 0%	27 1%	8 57%	2493 64%	3 21%	736 19%	0 0%	36 1%	3 21%	636 16%
MAY-2019	0 0%	27 1%	19 68%	2554 64%	6 21%	746 19%	0 0%	37 1%	3 11%	634 16%
JUN-2019	0 0%	27 1%	10 77%	2556 65%	3 23%	743 19%	0 0%	37 1%	0 0%	624 16%
JUL-2019	0 0%	27 1%	13 81%	2603 65%	3 19%	755 19%	0 0%	38 1%	0 0%	628 16%
AUG-2019	0 0%	27 1%	24 86%	2647 65%	1 4%	755 19%	0 0%	36 1%	3 11%	625 15%
SEP-2019	0 0%	28 1%	7 47%	2648 65%	6 40%	757 19%	0 0%	37 1%	2 13%	627 15%
OCT-2019	0 0%	28 1%	13 87%	2717 66%	1 7%	758 18%	0 0%	34 1%	1 7%	628 15%
NOV-2019	3 13%	88 2%	16 70%	2741 65%	4 17%	770 18%	0 0%	33 1%	0 0%	621 15%
DEC-2019	12 63%	230 5%	6 32%	2717 64%	1 5%	744 18%	0 0%	33 1%	0 0%	606 14%
JAN-2020	9 50%	421 10%	7 39%	2688 62%	0 0%	707 16%	0 0%	32 1%	2 11%	594 14%
FEB-2020	14 52%	602 14%	11 41%	2645 60%	2 7%	654 15%	0 0%	29 1%	0 0%	576 13%
MAR-2020	19 68%	755 17%	7 25%	2625 58%	1 4%	624 14%	1 4%	30 1%	0 0%	562 12%
APR-2020	7 50%	830 18%	6 43%	2592 57%	1 7%	608 13%	0 0%	29 1%	0 0%	544 12%
MAY-2020	10 56%	913 20%	6 33%	2562 56%	2 11%	598 13%	0 0%	27 1%	0 0%	541 12%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





### 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2019	1830	24.75	1481	20.03	3061	41.40	100	1.35	53	0.72	868	11.74
FEB-2019	1802	24.46	1478	20.06	3072	41.69	99	1.34	49	0.67	868	11.78
MAR-2019	1794	24.22	1471	19.86	3124	42.18	98	1.32	50	0.68	870	11.75
APR-2019	1760	23.92	1458	19.82	3135	42.61	100	1.36	48	0.65	857	11.65
MAY-2019	1773	23.91	1448	19.53	3196	43.10	97	1.31	45	0.61	857	11.56
JUN-2019	1739	23.63	1438	19.54	3195	43.42	95	1.29	48	0.65	844	11.47
JUL-2019	1713	23.24	1427	19.36	3236	43.90	92	1.25	48	0.65	855	11.60
AUG-2019	1686	22.89	1402	19.03	3295	44.73	94	1.28	50	0.68	839	11.39
SEP-2019	1698	23.14	1361	18.54	3298	44.94	93	1.27	51	0.69	838	11.42
OCT-2019	1703	23.04	1339	18.12	3357	45.43	93	1.26	52	0.70	846	11.45
NOV-2019	1667	22.70	1272	17.32	3424	46.63	91	1.24	50	0.68	839	11.43
DEC-2019	1644	22.39	1248	16.99	3484	47.44	92	1.25	48	0.65	828	11.27
JAN-2020	1616	21.97	1209	16.43	3563	48.43	87	1.18	56	0.76	826	11.23
FEB-2020	1573	21.46	1154	15.74	3646	49.73	85	1.16	59	0.80	814	11.10
MAR-2020	1542	20.86	1134	15.34	3757	50.83	85	1.15	51	0.69	822	11.12
APR-2020	1526	20.57	1128	15.20	3814	51.41	85	1.15	51	0.69	815	10.99
MAY-2020	1516	20.45	1115	15.04	3837	51.75	83	1.12	51	0.69	813	10.96

**Definitions:**

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month





**2.11 Baseline CD4 for Antiretroviral First Starts**

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2019	20	3	3	2	4	6	390
FEB-2019	16	1	0	6	4	4	400
MAR-2019	13	1	2	1	5	4	450
APR-2019	15	3	3	1	2	4	340
MAY-2019	21	1	0	6	8	4	440
JUN-2019	13	2	1	1	2	5	430
JUL-2019	13	1	1	1	3	7	530
AUG-2019	18	0	1	6	4	6	390
SEP-2019	15	0	0	2	4	7	530
OCT-2019	13	1	1	4	4	3	380
NOV-2019	17	4	1	1	1	10	520
DEC-2019	12	0	2	4	2	4	350
JAN-2020	12	0	2	1	4	4	490
FEB-2020	19	5	1	5	3	5	320
MAR-2020	23	4	0	3	1	10	550
APR-2020	8	0	0	3	0	5	686
MAY-2020	15	1	0	3	3	7	460

**Definitions:**

**First Starts** defined as starting ARV treatment in the specified month for the first time (ARV naive)

**Baseline CD4** is defined as most recent CD4 test before ARV start







**2.12 DTP Participants with PVL Measurement within previous five years, and never on ART**

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2019	12252	3830
FEB-2019	12260	3829
MAR-2019	12290	3859
APR-2019	12316	3882
MAY-2019	12332	3883
JUN-2019	12332	3888
JUL-2019	12349	3903
AUG-2019	12381	3920
SEP-2019	12400	3938
OCT-2019	12434	3962
NOV-2019	12456	3971
DEC-2019	12480	3986
JAN-2020	12535	4032
FEB-2020	12566	4049
MAR-2020	12566	4039
APR-2020	12544	4015
MAY-2020	12535	4004

**Definitions:**

**Patients with PVL test** are defined as having at least one PVL test within previous five years, and not reported deceased/moved

**Never on ART** are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants  
May 2020

N = 7415

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY







3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participants

May 2020

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



KELOWNA BY POSTAL CODE







3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

May 2020

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

May 2020

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

May 2020

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

May 2020

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





### 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	7	7	*
	35-49	9	10	*
	50+	27	39	*
	<b>Total HSDA:</b>	<b>43</b>	<b>56</b>	<b>29</b>
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HSDA:</b>	<b>74</b>	<b>98</b>	<b>57</b>	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HSDA:</b>	<b>367</b>	<b>498</b>	<b>284</b>	
THOMPSON/CARIBOO/ SHUSWAP	20-34	19	19	13
	35-49	70	75	57
	50+	108	177	83
	<b>Total HSDA:</b>	<b>197</b>	<b>271</b>	<b>153</b>
<b>Total HA:</b>		<b>681</b>	<b>923</b>	<b>523</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HA:</b>		<b>681</b>	<b>923</b>	<b>523</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	543	736	420
Female	138	187	103

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	523	55	620	35

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)







### 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	21	13
	5 years or more	10	6
	<5 years	12	10
	<b>Total HSDA:</b>	<b>43</b>	<b>29</b>
KOOTENAY BOUNDARY	10 years or more	47	36
	5 years or more	16	11
	<5 years	11	10
	<b>Total HSDA:</b>	<b>74</b>	<b>57</b>
OKANAGAN	10 years or more	230	167
	5 years or more	75	65
	<5 years	62	52
	<b>Total HSDA:</b>	<b>367</b>	<b>284</b>
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	111	83
	5 years or more	44	40
	<5 years	42	30
	<b>Total HSDA:</b>	<b>197</b>	<b>153</b>
<b>Total HA:</b>		<b>681</b>	<b>523</b>

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	409	299
5 years or more	145	122
<5 years	127	102
<b>Total HA:</b>	<b>681</b>	<b>523</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





### 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	46	64	15	26
KOOTENAY BOUNDARY	75	123	26	46
OKANAGAN	223	933	59	283
THOMPSON/CARIBOO/SHUSWAP	139	520	36	136
<b>Total:</b>	<b>483</b>	<b>1640</b>	<b>136</b>	<b>491</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
<b>Total:</b>	<b>93</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





#### 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	6	6	6
	20-34	35	37	27
	35-49	98	107	74
	50+	244	321	193
	<b>Total HSDA:</b>	<b>383</b>	<b>471</b>	<b>300</b>
FRASER NORTH	0-19	6	6	*
	20-34	119	119	*
	35-49	342	370	*
	50+	586	917	*
	<b>Total HSDA:</b>	<b>1053</b>	<b>1412</b>	<b>800</b>
FRASER SOUTH	0-19	6	6	*
	20-34	112	114	*
	35-49	327	370	*
	50+	558	825	*
	<b>Total HSDA:</b>	<b>1003</b>	<b>1315</b>	<b>809</b>
<b>Total HA:</b>		<b>2439</b>	<b>3198</b>	<b>1909</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	18	18	12
	20-34	266	270	190
	35-49	767	847	605
	50+	1388	2063	1102
<b>Total HA:</b>		<b>2439</b>	<b>3198</b>	<b>1909</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1848	2447	1454
Female	591	751	455

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	1909	52	630	35

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





#### 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration FRASER Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	226	176
	5 years or more	76	62
	<5 years	81	62
	<b>Total HSDA:</b>	<b>383</b>	<b>300</b>
FRASER NORTH	10 years or more	593	421
	5 years or more	258	212
	<5 years	202	167
	<b>Total HSDA:</b>	<b>1053</b>	<b>800</b>
FRASER SOUTH	10 years or more	574	458
	5 years or more	216	168
	<5 years	213	183
	<b>Total HSDA:</b>	<b>1003</b>	<b>809</b>
<b>Total HA:</b>		<b>2439</b>	<b>1909</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1393	1055
	5 years or more	550	442
	<5 years	496	412
<b>Total HA:</b>		<b>2439</b>	<b>1909</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





#### 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries FRASER Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	142	496	30	50
FRASER NORTH	251	1587	50	237
FRASER SOUTH	217	1500	48	433
<b>Total:</b>	<b>610</b>	<b>3583</b>	<b>128</b>	<b>720</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	209
FRASER NORTH	662
FRASER SOUTH	480
<b>Total:</b>	<b>1351</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender  
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>344</b>	<b>494</b>
RICHMOND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>182</b>	<b>231</b>
VANCOUVER	0-19	20	20	8
	20-34	454	469	319
	35-49	1356	1521	967
	50+	2855	4901	2067
	<b>Total HSDA:</b>	<b>4685</b>	<b>6911</b>	<b>3361</b>
<b>Total HA:</b>		<b>5211</b>	<b>7636</b>	<b>3785</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	24	24	10
	20-34	512	528	364
	35-49	1481	1657	1064
	50+	3194	5427	2347
<b>Total HA:</b>		<b>5211</b>	<b>7636</b>	<b>3785</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Unknown	2	2	0
Male	4606	6710	3334
Female	603	924	451

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	3785	54	640	35

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	192	154
	5 years or more	90	73
	<5 years	62	55
	<b>Total HSDA:</b>	<b>344</b>	<b>282</b>
RICHMOND	10 years or more	102	73
	5 years or more	37	30
	<5 years	43	39
	<b>Total HSDA:</b>	<b>182</b>	<b>142</b>
VANCOUVER	10 years or more	2855	1955
	5 years or more	1087	794
	<5 years	743	612
	<b>Total HSDA:</b>	<b>4685</b>	<b>3361</b>
<b>Total HA:</b>		<b>5211</b>	<b>3785</b>

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	3149	2182
5 years or more	1214	897
<5 years	848	706
<b>Total HA:</b>	<b>5211</b>	<b>3785</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries  
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	179	502	58	170
RICHMOND	44	291	12	93
VANCOUVER	624	10978	210	5259
<b>Total:</b>	<b>847</b>	<b>11771</b>	<b>280</b>	<b>5522</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
<b>Total:</b>	<b>98</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA







**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender  
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>331</b>	<b>467</b>
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>128</b>	<b>170</b>
SOUTH VANCOUVER ISLAND	0-19	*	*	0
	20-34	*	*	56
	35-49	*	*	149
	50+	*	*	369
	<b>Total HSDA:</b>		<b>748</b>	<b>1062</b>
<b>Total HA:</b>		<b>1207</b>	<b>1699</b>	<b>946</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HA:</b>		<b>1207</b>	<b>1699</b>	<b>946</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1002	1404	788
Female	205	295	158

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	946	55	580	35

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	186	152
	5 years or more	75	61
	<5 years	70	55
	<b>Total HSDA:</b>	<b>331</b>	<b>268</b>
NORTH VANCOUVER ISLAND	10 years or more	73	59
	5 years or more	37	29
	<5 years	18	16
	<b>Total HSDA:</b>	<b>128</b>	<b>104</b>
SOUTH VANCOUVER ISLAND	10 years or more	432	310
	5 years or more	162	137
	<5 years	154	127
	<b>Total HSDA:</b>	<b>748</b>	<b>574</b>
<b>Total HA:</b>		<b>1207</b>	<b>946</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	691	521
	5 years or more	274	227
	<5 years	242	198
<b>Total HA:</b>		<b>1207</b>	<b>946</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





### 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries VANCOUVER ISLAND Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	199	873	77	194
NORTH VANCOUVER ISLAND	148	268	50	79
SOUTH VANCOUVER ISLAND	213	1812	46	565
<b>Total:</b>	<b>560</b>	<b>2953</b>	<b>173</b>	<b>838</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	49
NORTH VANCOUVER ISLAND	41
SOUTH VANCOUVER ISLAND	113
<b>Total:</b>	<b>203</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





### 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender NORTHERN Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>40</b>	<b>48</b>
NORTH WEST	20-34	9	10	5
	35-49	17	33	13
	50+	43	66	36
	<b>Total HSDA:</b>	<b>69</b>	<b>109</b>	<b>54</b>
NORTHERN INTERIOR	0-19	5	5	*
	20-34	23	24	*
	35-49	72	89	*
	50+	90	155	*
	<b>Total HSDA:</b>	<b>190</b>	<b>273</b>	<b>144</b>
<b>Total HA:</b>		<b>299</b>	<b>430</b>	<b>223</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	*
	20-34	33	35	*
	35-49	109	144	*
	50+	151	245	*
<b>Total HA:</b>		<b>299</b>	<b>430</b>	<b>223</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	180	264	134
Female	119	166	89

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	223	51	540	35

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration  
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	21	*
	5 years or more	14	*
	<5 years	5	*
	<b>Total HSDA:</b>	<b>40</b>	<b>25</b>
NORTH WEST	10 years or more	35	25
	5 years or more	22	19
	<5 years	12	10
	<b>Total HSDA:</b>	<b>69</b>	<b>54</b>
NORTHERN INTERIOR	10 years or more	80	60
	5 years or more	62	50
	<5 years	48	34
	<b>Total HSDA:</b>	<b>190</b>	<b>144</b>
<b>Total HA:</b>		<b>299</b>	<b>223</b>

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	136	97
5 years or more	98	78
<5 years	65	48
<b>Total HA:</b>	<b>299</b>	<b>223</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries  
NORTHERN Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	42	64	8	9
NORTH WEST	82	164	18	35
NORTHERN INTERIOR	117	472	19	189
<b>Total:</b>	<b>241</b>	<b>700</b>	<b>45</b>	<b>233</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	7
NORTH WEST	18
NORTHERN INTERIOR	13
<b>Total:</b>	<b>38</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





### 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	6	10	5
	KOOTENAY BOUNDARY	6	9	6
	OKANAGAN	24	40	15
	THOMPSON/CARIBOO/SHUSWAP	27	49	23
	<b>Total HA:</b>	<b>63</b>	<b>108</b>	<b>49</b>
FRASER	FRASER EAST	39	49	32
	FRASER NORTH	55	91	46
	FRASER SOUTH	78	111	58
	<b>Total HA:</b>	<b>172</b>	<b>251</b>	<b>136</b>
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	25	48	21
	RICHMOND	8	13	6
	VANCOUVER	482	864	387
	<b>Total HA:</b>	<b>515</b>	<b>925</b>	<b>414</b>
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	51	80	42
	NORTH VANCOUVER ISLAND	20	29	18
	SOUTH VANCOUVER ISLAND	41	85	35
	<b>Total HA:</b>	<b>112</b>	<b>194</b>	<b>95</b>
NORTHERN	NORTH EAST	11	13	10
	NORTH WEST	26	57	20
	NORTHERN INTERIOR	74	113	63
	<b>Total HA:</b>	<b>111</b>	<b>183</b>	<b>93</b>
<b>Total:</b>		<b>973</b>	<b>1661</b>	<b>787</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	612	1063	492
Female	361	598	295

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total:</b>	787	51	490	35

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





## 5.1 Drug Names and Definitions

**Abacavir (Ziagen, ABC):** a NUCLEOSIDE ANALOG from ViiV Healthcare.

**Active:** persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

**Amphotericin B (Fungilin):** a drug used for treatment of candidiasis and other fungal infections.

**Amprenavir (Agenerase, APV):** a PROTEASE INHIBITOR from ViiV Healthcare. No longer marketed in Canada.

**Antiretroviral (ARV):** a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

**Atazanavir (Reyataz, ATV):** a PROTEASE INHIBITOR from Bristol-Myers Squibb.

**Atovaquone (Mepron):** a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

**Atripla (ATP):** the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

**Azithromycin (Zithromax):** an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

**Bictegravir:** an INTEGRASE INHIBITOR from Gilead Sciences.

**Boosted PI:** a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

**CD4 Cell Count:** the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

**Chemokine Receptor Inhibitor:** a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

**Clarithromycin (Biaxin):** an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

**Cobicistat:** a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

**Combination Therapy:** initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

**Combivir (CBV):** the ViiV Healthcare trade name for a tablet containing both ZIDOVUDINE and LAMIVUDINE.

**Complera (CPL):** the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

**Darunavir (Prezista, DRV):** a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

**Deceased:** persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.







## Monthly Report

**Descovy (DSC):** the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

**Didanosine (Videx, DDI):** a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

**Dolutegravir (Tivicay, DTG):** an INTEGRASE INHIBITOR from ViiV Healthcare.

**Doravirine:** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Merck.

**Efavirenz (Sustiva, Auro efavirenz, EFV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

**Elvitegravir (EGV):** an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

**Emtricitabine (FTC):** a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

**Enfuvirtide (Fuzeon, T20):** a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

**Entry Inhibitor:** a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

**Etravirine (Intelence, ETV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

**Ethambutol (Myambutol):** an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

**First started program:** a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

**Fosamprenavir (Telzir, fAPV):** a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

**Fusion Inhibitor:** a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

**Genvoya (GNV):** the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

**Granulocyte Colony Stimulating Factor (GCSF, Neupogen):** a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

**Health Authority:** refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

**Inactive:** persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

**Integrase Inhibitor:** a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

**Kivexa (KIV):** the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

**Lamivudine (3TC):** a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

**Lopinavir (Kaletra, LPV/r):** a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.





## Monthly Report

**Maraviroc (Celsentri, MVC):** a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

**Median (MED) age:** median age of participants in the HIV/AIDS Drug Treatment program in that time period.

**MDRT:** see MULTIPLE DRUG RESCUE THERAPY

**Moved out of BC:** a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

**Moxifloxacin:** a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

**Multiple Drug Rescue Therapy (MDRT or Mega-HAART):** the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

**Nelfinavir (Viracept, NFV):** a PROTEASE INHIBITOR from ViiV Healthcare.

**Net change:** the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

**Nevirapine (Viramune, NVP):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

**NNRTI:** see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

**NNRTI / no PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

**Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI):** a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

**NRTI:** see NUCLEOSIDE ANALOG.

**Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI):** a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

**Nucleotide Analog:** ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

**Octreotide Acetate (Sandostatin):** a drug used to treat chronic refractory diarrhea.

**Odefsey (ODF):** the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

**One or more PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

**Other:** an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

**Paromomycin (Humatin):** an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.





## Monthly Report

**Pentamidine:** an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

**PI:** see PROTEASE INHIBITOR.

**Prezcobix (PZC):** the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

**Prodrug:** a compound that is converted within the body into the active form that has medical effects.

**Protease Inhibitor:** a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

**Raltegravir (RGV, Isentress):** an INTEGRASE INHIBITOR from Merck.

**Restarted/ changed therapy (Tx):** a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

**Rifabutin (Mycobutin):** an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

**Rilpivirine (Edurant, RPV):** a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

**Ritonavir (Norvir, RTV):** a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

**Saquinavir (Invirase, SQV):** a PROTEASE INHIBITOR from Hoffman-La Roche.

**Stavudine (Zerit, d4T):** a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

**Stopped all therapies (Tx):** a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

**Stribild (STR):** the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

**Tenofovir alafenamide (Tenofovir AF, TAF):** a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

**Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF):** a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

**Tipranavir (Aptivus, TPV):** a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

**Triple Therapy:** the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

**Triumeq (TRQ):** the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

**Trizivir (TRZ):** the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

**Truvada (TRU):** the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.





## Monthly Report

---

**Valganciclovir:** an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

**Viral Load:** the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

**Zidovudine (Retrovir, AZT):** a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

